Barclays
FPRX

Barclays’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Barclays’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-134,300
Closed -$5.37M – 6763
2016
Q1 		$5.37M Hold
134,300
– – 0.01% 1128
2015
Q4 		$5.51M Buy
+134,300
New +$4.5M 0.01% 1248

Barclays's FPRX Position: Q2 2021 in Review

Barclays sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 136,346 shares — an estimated $5.14M sold.

Barclays first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $5.14M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Barclays reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Barclays sold 136,346 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $5.14M.
  • Barclays first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
  • Barclays's Five Prime Therapeutics, Inc. position peaked at $5.14M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.